HYD receives GMP certification
Hungarian cancer research and drug developer HYD was awarded good manufacturing practice (GMP) certification and, simultaneously registered depleted-deuterium as an active ingredient with the European Medicines Agency, the company told Hungarian news agency MTI today.
According to MTI, the certification brings HYD another step closer to the registration of its depleted-deuterium water (DDW) as a medical treatment for cancer, clearing the way for clinical tests, the company said. The company expects to see DDW become a medicine “within a few years,” the company reportedly said.
Last year the company wound up a HUF 250 mln DDW production facility, supported by venture capital fund manager Primus Capital and a HUF 17 mln European Union grant.
The company foresees Primus Capital contributing a further HUF 400-500 mln for clinical testing. The company is reportedly in talks with a foreign drugmaker on the sale of technology.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.